Lilly sees quick return on $2.3B Ajax buy as blood cancer drug shows early efficacy

Eli Lilly’s new JAK2 inhibitor—which it obtained from the recent acquisition of Ajax Therapeutics—reduced spleen volume by more than a third in 70% of patients with myelofibrosis.